Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)

NCT ID: NCT04906460

Last Updated: 2025-12-15

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 26 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-09-28
• Study Completion Date: 2027-04-24

Brief Summary

This is a Phase 1b/2 open-label study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical effects of intravenous (IV) WVE-N531 in patients with Duchenne muscular dystrophy (DMD). To participate in the study, patients must have a documented mutation of the DMD gene that is amenable to exon 53 skipping intervention. This study has 3 parts, Part A, Part B, including Part B Extension Arm, and Part C. Part A is completed. Part B is completed. Following completion of Part B, all patients elected to continue to receive study drug in the optional Part B open-label Extension Arm. Part C has been added to the study and will enroll new patients.

Detailed Description

Following completion of Part A, eligible patients rolled over into Part B to continue to receive treatment. In addition, new patients were enrolled up to a total of 11 patients in Part B. All patients received WVE-N531 at 10 mg/kg every other week (Q2W) until competent authority approval of a protocol update, when all patients were switched to Q4W dosing. Muscle biopsies were performed following 24 weeks and for new Part B patients (those that did not take part in Part A) following 48 weeks of treatment. Following completion of Part B, all patients elected to continue to receive study drug at Q4W for up to 1 year in an optional Part B Extension Arm.

For this portion of the study, up to 15 new patients will be enrolled into Part C of the study. All patients will undergo an open muscle biopsy, at baseline and following 24 weeks of treatment.

The primary endpoint for Part B is the measurement of dystrophin protein levels. Participants will also be evaluated for safety, tolerability, digital and functional endpoints.

The primary endpoint for Part C is the measurement of dystrophin protein levels. Participants will also be evaluated for safety, tolerability, digital and functional endpoints. Safety monitoring will occur through 10 months after the last dose.

Conditions

Duchenne Muscular Dystrophy

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

WVE-N531

Group Type: EXPERIMENTAL

WVE-N531

Intervention Type: DRUG

WVE-N531 is an antisense oligonucleotide (ASO)

Interventions

WVE-N531

WVE-N531 is an antisense oligonucleotide (ASO)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

Part A and Part B:

1. Part A patients may be screened for Part B upon completion of a washout period of ≥18 weeks from last dose in Part A. New patients may also be screened for Part B

2. Diagnosis of DMD based on clinical phenotype.

3. Documented mutation in the DMD gene associated with DMD that is amenable to exon 53 intervention

4. Score of ≥1 on item 1 or 2 of the shoulder component of the Performance of the Upper Limb (PUL) (Part B ).

5. Ambulatory or non-ambulatory male

6. Stable pulmonary and cardiac function, as measured by the following: (Part B):

1. Reproducible percent predicted forced vital capacity (FVC) ≥50%; 2. Left ventricular ejection fraction (LVEF) >55% in patients <10 years of age and >45% in patients ≥10 years of age, as measured (and documented) by echocardiogram (ECHO) and/or cardiac magnetic resonance imaging (MRI), within 6 months prior to enrollment into the study.

7.Adequate muscle at Screening to perform open muscle biopsies, preferably deltoid.

8. Currently on a stable corticosteroid therapy regimen, defined as initiation of systemic corticosteroid therapy that occurred ≥6 months prior to Screening and no changes in dose ≤3 months prior to Screening visit (Part B ).

Part C

1. New patients to be screened for Part C.

2. Diagnosis of DMD based on clinical phenotype.

3. Documented mutation in the DMD gene associated with DMD that is amenable to exon 53 intervention

4. Score of ≥1 on item 1 or 2 of the shoulder component of the Performance of the Upper Limb (PUL) .

5. Ambulatory male

6. Stable pulmonary and cardiac function, as measured by the following:

1. Reproducible percent predicted forced vital capacity (FVC) ≥50%; 2. Left ventricular ejection fraction (LVEF) >55% in patients as measured (and documented) by echocardiogram (ECHO) and/or cardiac magnetic resonance imaging (MRI), within 6 months prior to enrollment into the study.

7. Adequate muscle at Screening to perform open muscle biopsies, preferably deltoid.

8. Currently on a stable corticosteroid therapy regimen, defined as initiation of systemic corticosteroid therapy that occurred ≥6 months prior to Screening and no changes in dose ≤3 months prior to Screening visit .

Exclusion Criteria

1. Clinically significant medical finding on the physical examination other than DMD that, in the judgment of the Investigator, will make the patient unsuitable for participation in, and/or completion of the study procedures.

2. Part B and Part C: Major surgery within 3 months prior to Day 1 or planned major surgery for any time during the study.

3. Part B: Diagnosis of active alcohol, cannabinoid, or other substance use disorder (except nicotine) within 6 months prior to the Screening visit

4. Part C: Any recreational substance use (including prescribed cannabinoids), with the exception of nicotine, irrespective of legality, within 2 months prior to Screening and/or unwilling to refrain from such use for the duration of the study.

• Minimum Eligible Age: 4 Years
• Maximum Eligible Age: 18 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Wave Life Sciences Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Director, MD

Role: STUDY_DIRECTOR

Wave Life Sciences

Locations

Arkansas Children's Hospital

Little Rock, Arkansas, United States

Site Status: RECRUITING

Rare Disease Research LLC

Atlanta, Georgia, United States

Site Status: RECRUITING

Istiklal Hospital/ Clinical Research Unit

Amman, , Jordan

Site Status: RECRUITING

The Specialty Hospital (TSH)/ Advanced Clinical Center

Amman, , Jordan

Site Status: RECRUITING

Oxford Children's Hospital, Oxford University Hospitals NHS Foundation Trust

Headington, Oxford, United Kingdom

Site Status: RECRUITING

Countries

United States; Jordan; United Kingdom

Central Contacts

Clinical Operations

Role: CONTACT

clinicaltrials@wavelifesci.com

855-215-4687

Facility Contacts

Aravindhan Veerapandiyan, Dr

Role: primary

aveerapandiyan@uams.edu

501-364-1850

Scott Batchelor, Dr

Role: primary

sbatchelor@rarediseaseresearch.com

404-782-8239

Muath Alqurashi, Dr

Role: primary

drmuathalqurashi@yahoo.com

Mai Bader, Dr

Role: primary

dr.mai.bader@hotmail.com

Laurent Servais, MD, PhD

Role: primary

Laurent.Servais@ouh.nhs.uk

01865 227503

Other Identifiers

WVE-N531-001

Identifier Type: -

Identifier Source: org_study_id